• 1. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383
• 2. An atmosphere and light tuned highly diastereoselective synthesis of cyclobuta/penta[b]indoles from aniline-tethered alkylidenecyclopropanes with alkynes?
  Bo Cao,Yin Wei Chem. Commun., 2018,54, 2870-2873
• 3. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996
• 4. An air-stable organometallic polymer containing titanafluorene moieties obtained by the Sonogashira–Hagihara cross-coupling polycondensation?
  Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043
• 5. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514

Prosta-5,13-dien-1-oicacid, 9,11,15-trihydroxy-, (5Z,8b,9b,11a,13E,15S)-: A Comprehensive Overview in Modern Chemical Biology

The compound with the CAS number 177020-26-7 is a highly specialized molecule with the systematic name Prosta-5,13-dien-1-oicacid, 9,11,15-trihydroxy-, (5Z,8b,9b,11a,13E,15S)-. This intricate structure has garnered significant attention in the field of chemical biology due to its unique chemical properties and potential biological activities. The molecule is characterized by a complex arrangement of double bonds and hydroxyl groups, which contribute to its reactivity and functionality.

In recent years, there has been a growing interest in polyunsaturated fatty acids (PUFAs) and their derivatives for their diverse biological roles. The specific configuration of double bonds and hydroxyl groups in this compound suggests that it may exhibit potent effects on various physiological pathways. Specifically, the presence of multiple hydroxyl groups at positions 9, 11, and 15 indicates a high degree of functionalization that could influence its interactions with biological targets.

One of the most compelling aspects of this compound is its potential role in modulating inflammatory responses. Inflammatory processes are mediated by a complex interplay of signaling molecules and pathways, many of which involve PUFAs. The structural features of Prosta-5,13-dien-1-oicacid, 9,11,15-trihydroxy-, (5Z,8b,9b,11a,13E,15S)- suggest that it could interact with enzymes such as cyclooxygenases (COX) and lipoxygenases (LOX), which are key players in the synthesis of pro-inflammatory mediators. By inhibiting or modulating these enzymes, the compound may have therapeutic potential in conditions characterized by excessive inflammation.

Furthermore, the stereochemistry of the molecule is critical to its biological activity. The specific arrangement of double bonds and hydroxyl groups at positions 5Z, 8b, 9b, 11a, 13E, and 15S dictates how the compound interacts with biological receptors and enzymes. This precise stereochemical configuration ensures that the molecule can bind effectively to its targets while minimizing off-target effects. Such selectivity is essential for developing safe and effective therapeutic agents.

Recent studies have begun to explore the pharmacological properties of this compound in vitro and in vivo. Preliminary research indicates that it may possess anti-inflammatory and anti-proliferative effects. These findings are particularly intriguing given the increasing evidence linking PUFAs to various chronic diseases. For instance， studies have shown that PUFAs can modulate immune cell function and reduce oxidative stress， both of which are key mechanisms in the pathogenesis of chronic inflammatory diseases.

The synthesis of Prosta-5,13-dien-1-oicacid，9，11，15-trihydroxy-, (5Z，8b，9b，11a，13E，15S)- represents a significant challenge due to its complex structure. Advanced synthetic methodologies are required to achieve the desired stereochemical purity. Techniques such as stereoselective hydrogenation and epoxide ring-opening reactions have been employed to construct the core framework of the molecule. These synthetic strategies ensure that the final product retains its biological activity by maintaining the correct stereochemical configuration.

In addition to its potential therapeutic applications， this compound has also attracted interest for its role as a research tool. Biologists and biochemists use such molecules to study enzyme mechanisms and identify new drug targets. By understanding how this compound interacts with biological systems， researchers can gain insights into disease pathways and develop more effective treatments.

The future direction of research on this compound will likely focus on optimizing its pharmacological properties through structural modifications。 By fine-tuning its chemical structure， scientists hope to enhance its bioavailability、reduce toxicity、and improve its efficacy。 Additionally， preclinical studies will be essential to evaluate its safety and effectiveness in animal models before human clinical trials can be initiated.

In conclusion，Prosta-5，13-dien-1-oicacid，9，11，15-trihydroxy-, (5Z，8b，9b，11a，13E，15S)-(CAS no.177020-26-7) is a promising molecule with significant potential in chemical biology。 Its unique structural features、potential biological activities、and synthetic challenges make it a subject of intense research interest。 As our understanding of PUFAs and their derivatives continues to grow， this compound will likely play an important role in the development of new therapeutic strategies for various diseases.

• 27415-26-5(8-epi-Prostaglandin F2α)
• 10164-73-5(7-((1R,2R,3R,5R)-3,5-Dihydroxy-2-((S,E)-3-hydroxyoct-1-en-1-yl)cyclopentyl)heptanoic acid)
• 36150-01-3(Prosta-5,13-dien-1-oicacid, 9,11,15-trihydroxy-, (5E,9a,11a,13E,15S)-)
• 58551-69-2(Carboprost tromethamine)
• 551-11-1(Dinoprost)
• 221664-05-7(2,3-Dinor iPF2α-III)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)